WHAT IS CLAIMED IS:

1. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

2. The isolated polynucleotide of claim 1, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 3.

3. The isolated polynucleotide of claim 1, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 4.

4. The isolated polynucleotide of claim 1, wherein said polypeptide is as set forth in SEQ ID NO: 1.

5. The isolated polynucleotide of claim 1, wherein said polypeptide is as set forth in SEQ ID NO: 2.

6. An isolated polynucleotide as set forth in SEQ ID NO: 4.

7. An isolated polynucleotide as set forth in SEQ ID NO: 3.

8. An isolated polypeptide as set forth in SEQ ID NO: 1.

9. An isolated polypeptide as set forth in SEQ ID NO: 2.

10. A nucleic acid construct comprising the isolated polynucleotide of claim 1.

11. The nucleic acid construct of claim 10, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

12. The nucleic acid construct of claim 10, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

13. A host cell comprising the nucleic acid construct of claim 10.

14. An isolated polypeptide comprising an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

15. An antibody or an antibody fragment being capable of specifically binding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

16. An oligonucleotide specifically hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

17. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

18. A method of treating Met-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters, thereby treating the Met-related disease in a subject.

19. The method of claim 18, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

20. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

21. The isolated polynucleotide of claim 20, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 8.

22. The isolated polynucleotide of claim 20, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 7.

23. The isolated polynucleotide of claim 20, wherein said polypeptide is as set forth in SEQ ID NO: 5.

24. The isolated polynucleotide of claim 20, wherein said polypeptide is as set forth in SEQ ID NO: 6.

25. An isolated polynucleotide as set forth in SEQ ID NO: 8.

26. An isolated polynucleotide as set forth in SEQ ID NO: 7.

27. An isolated polypeptide as set forth in SEQ ID NO: 5.

28. An isolated polypeptide as set forth in SEQ ID NO: 6.

29. A nucleic acid construct comprising the isolated polynucleotide of claim 20.

30. The nucleic acid construct of claim 29, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

31. The nucleic acid construct of claim 29, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

32. A host cell comprising the nucleic acid construct of claim 29.

33. An isolated polypeptide comprising an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

34. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

35. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

36. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

37. A method of treating an IL-6-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5 as determined using the

LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters, thereby treating the IL-6-related disease in the subject.

38. The Method of claim 37, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

39. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

40. The isolated polynucleotide of claim 39, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 11.

41. The isolated polynucleotide of claim 39, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 12.

42. The isolated polynucleotide of claim 39, wherein said polypeptide is as set forth in SEQ ID NO: 9.

43. The isolated polynucleotide of claim 39, wherein said polypeptide is as set forth in SEQ ID NO: 10.

44. An isolated polynucleotide as set forth in SEQ ID NO: 11.

45. An isolated polynucleotide as set forth in SEQ ID NO: 12.

46. An isolated polypeptide as set forth in SEQ ID NO: 10.

47. An isolated polypeptide as set forth in SEQ ID NO: 9.

48. A nucleic acid construct comprising the isolated polynucleotide of claim 39.

49. The nucleic acid construct of claim 48, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

50. The nucleic acid construct of claim 48, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

51. A host cell comprising the nucleic acid construct of claim 48.

52. An isolated polypeptide comprising an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

53. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

54. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

55. A pharmaceutical composition comprising a therapeutically effective amount of a IL-7 polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

56. A method of treating IL-7-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

57. The method of claim 56, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

58. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

59. The isolated polynucleotide of claim 58, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 15.

60. The isolated polynucleotide of claim 58, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 16.

61. The isolated polynucleotide of claim 58, wherein said polypeptide is as set forth in SEQ ID NO: 13.

62. The isolated polynucleotide of claim 58, wherein said polypeptide is as set forth in SEQ ID NO: 14.

63. An isolated polynucleotide as set forth in SEQ ID NO: 15.

64. An isolated polynucleotide as set forth in SEQ ID NO: 16.

65. An isolated polypeptide as set forth in SEQ ID NO: 13.

66. An isolated polypeptide as set forth in SEQ ID NO: 14.

67. A nucleic acid construct comprising the isolated polynucleotide of claim 58.

68. The nucleic acid construct of claim 67, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

69. The nucleic acid construct of claim 67, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

70. A host cell comprising the nucleic acid construct of claim 67.

71. An isolated polypeptide comprising an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

72. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

73. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

74. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 85 % identical to

SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

75. A method of treating IL-7-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

76. The method of claim 75, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

77. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

78. The isolated polynucleotide of claim 77, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 19.

79. The isolated polynucleotide of claim 77, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 20.

80. The isolated polynucleotide of claim 77, wherein said polypeptide is as set forth in SEQ ID NO: 17.

81. The isolated polynucleotide of claim 77, wherein said polypeptide is as set forth in SEQ ID NO: 18.

82. An isolated polynucleotide as set forth in SEQ ID NO: 19.

83. An isolated polynucleotide as set forth in SEQ ID NO: 20.

84. An isolated polypeptide as set forth in SEQ ID NO: 17.

85. An isolated polypeptide as set forth in SEQ ID NO: 18.

86. A nucleic acid construct comprising the isolated polynucleotide of claim 77.

87. The nucleic acid construct of claim 86, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

88. The nucleic acid construct of claim 86, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

89. A host cell comprising the nucleic acid construct of claim 86.

90. An isolated polypeptide comprising an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

91. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

92. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 60 % identical to SEQ ID NO: 17, as

determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

93. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

94. A method of treating TNFR9-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

95. The method of claim 94, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

96. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

97. The isolated polynucleotide of claim 96, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 27.

98. The isolated polynucleotide of claim 96, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 28.

99. The isolated polynucleotide of claim 96, wherein said polypeptide is as set forth in SEQ ID NO: 25.

100. The isolated polynucleotide of claim 96, wherein said polypeptide is as set forth in SEQ ID NO: 26.

101. An isolated polynucleotide as set forth in SEQ ID NO: 27.

102. An isolated polynucleotide as set forth in SEQ ID NO: 28.

103. An isolated polypeptide as set forth in SEQ ID NO: 25.

104. An isolated polypeptide as set forth in SEQ ID NO: 26.

105. A nucleic acid construct comprising the isolated polynucleotide of claim 96.

106. The nucleic acid construct of claim 105, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

107. The nucleic acid construct of claim 105, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

108. A host cell comprising the nucleic acid construct of claim 105.

109. An isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

110. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25,

as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

111. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

112. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

113. A method of treating IL-4R-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

114. The method of claim 113, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

115. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

116. The isolated polynucleotide of claim 115, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 24.

117. The isolated polynucleotide of claim 115, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 23.

118. The isolated polynucleotide of claim 115, wherein said polypeptide is as set forth in SEQ ID NO: 21.

119. The isolated polynucleotide of claim 115, wherein said polypeptide is as set forth in SEQ ID NO: 22.

120. An isolated polynucleotide as set forth in SEQ ID NO: 23.

121. An isolated polynucleotide as set forth in SEQ ID NO: 24.

122. An isolated polypeptide as set forth in SEQ ID NO: 21.

123. An isolated polypeptide as set forth in SEQ ID NO: 22.

124. A nucleic acid construct comprising the isolated polynucleotide of claim 115.

125. The nucleic acid construct of claim 124, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

126. The nucleic acid construct of claim 124, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

127. A host cell comprising the nucleic acid construct of claim 124.

128. An isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

129. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

130. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

131. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

132. A method of treating IL-4R-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

133. The method of claim 132, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

134. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

135. The isolated polynucleotide of claim 134, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 31.

136. The isolated polynucleotide of claim 134, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 32.

137. The isolated polynucleotide of claim 134, wherein said polypeptide is as set forth in SEQ ID NO: 29.

138. The isolated polynucleotide of claim 134, wherein said polypeptide is as set forth in SEQ ID NO: 30.

139. An isolated polynucleotide as set forth in SEQ ID NO: 31.

140. An isolated polynucleotide as set forth in SEQ ID NO: 32.

141. An isolated polypeptide as set forth in SEQ ID NO: 29.

142. An isolated polypeptide as set forth in SEQ ID NO: 30.

143. A nucleic acid construct comprising the isolated polynucleotide of claim 134.

144. The nucleic acid construct of claim 143, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

145. The nucleic acid construct of claim 143, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

146. A host cell comprising the nucleic acid construct of claim 143.

147. An isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

148. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

149. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

150. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

151. A method of treating TGR2-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

152. The method of claim 151, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

153. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

154. The isolated polynucleotide of claim 153, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 35.

155. The isolated polynucleotide of claim 153, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 36.

156. The isolated polynucleotide of claim 153, wherein said polypeptide is as set forth in SEQ ID NO: 33.

157. The isolated polynucleotide of claim 153, wherein said polypeptide is as set forth in SEQ ID NO: 34.

158. An isolated polynucleotide as set forth in SEQ ID NO: 35.

159. An isolated polynucleotide as set forth in SEQ ID NO: 36.

160. An isolated polypeptide as set forth in SEQ ID NO: 33.

161. An isolated polypeptide as set forth in SEQ ID NO: 34.

162. A nucleic acid construct comprising the isolated polynucleotide of claim 153.

163. The nucleic acid construct of claim 162, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

164. The nucleic acid construct of claim 162, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

165. A host cell comprising the nucleic acid construct of claim 162.

166. An isolated polypeptide comprising an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

167. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

168. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

169. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

170. A method of treating ITAV-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

171. The method of claim 170, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

172. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

173. The isolated polynucleotide of claim 172, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 39.

174. The isolated polynucleotide of claim 172, wherein said polypeptide is as set forth in SEQ ID NO: 37.

175. The isolated polynucleotide of claim 172, wherein said polypeptide is as set forth in SEQ ID NO: 38.

176. An isolated polynucleotide as set forth in SEQ ID NO: 39.

177. An isolated polypeptide as set forth in SEQ ID NO: 37.

178. An isolated polypeptide as set forth in SEQ ID NO: 38.

179. A nucleic acid construct comprising the isolated polynucleotide of claim 172.

180. The nucleic acid construct of claim 179, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

181. The nucleic acid construct of claim 179, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

182. A host cell comprising the nucleic acid construct of claim 179.

183. An isolated polypeptide comprising an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

184. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

185. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

186. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

187. A method of treating IL10-R-B-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

188. The method of claim 187, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

189. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

190. The isolated polynucleotide of claim 189, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 43.

191. The isolated polynucleotide of claim 189, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 40.

192. The isolated polynucleotide of claim 189, wherein said polypeptide is as set forth in SEQ ID NO: 41.

193. The isolated polynucleotide of claim 189, wherein said polypeptide is as set forth in SEQ ID NO: 42.

194. An isolated polynucleotide as set forth in SEQ ID NO: 43.

195. An isolated polynucleotide as set forth in SEQ ID NO: 40.

196. An isolated polypeptide as set forth in SEQ ID NO: 41.

197. An isolated polypeptide as set forth in SEQ ID NO: 42.

198. A nucleic acid construct comprising the isolated polynucleotide of claim 189.

199. The nucleic acid construct of claim 189, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

200. The nucleic acid construct of claim 189, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

201. A host cell comprising the nucleic acid construct of claim 198.

202. An isolated polypeptide comprising an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

203. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

204. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

205. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

206. A method of treating INR1-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41 as determined using the

LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

207. The method of claim 206, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.